92 related articles for article (PubMed ID: 10891891)
1. Tumor necrosis factor modulates CD 20 expression on cells from chronic lymphocytic leukemia: a new role for TNF alpha?
Sivaraman S; Deshpande CG; Ranganathan R; Huang X; Jajeh A; O'Brien T; Huang RW; Gregory SA; Venugopal P; Preisler HD
Microsc Res Tech; 2000 Aug; 50(3):251-7. PubMed ID: 10891891
[TBL] [Abstract][Full Text] [Related]
2. Anti-CD20 antibody (IDEC-C2B8, rituximab) enhances efficacy of cytotoxic drugs on neoplastic lymphocytes in vitro: role of cytokines, complement, and caspases.
Chow KU; Sommerlad WD; Boehrer S; Schneider B; Seipelt G; Rummel MJ; Hoelzer D; Mitrou PS; Weidmann E
Haematologica; 2002 Jan; 87(1):33-43. PubMed ID: 11801463
[TBL] [Abstract][Full Text] [Related]
3. Intracellular tumor necrosis factor production by T- and B-cells in B-cell chronic lymphocytic leukemia.
Bojarska-Junak A; Rolinski J; Wasik-Szczepaneko E; Kaluzny Z; Dmoszynska A
Haematologica; 2002 May; 87(5):490-9. PubMed ID: 12010662
[TBL] [Abstract][Full Text] [Related]
4. CD40 triggering enhances fludarabine-induced apoptosis of chronic lymphocytic leukemia B-cells through autocrine release of tumor necrosis factor-alpha and interferon-gama and tumor necrosis factor receptor-I-II upregulation.
de Totero D; Tazzari PL; Capaia M; Montera MP; Clavio M; Balleari E; Foa R; Gobbi M
Haematologica; 2003 Feb; 88(2):148-58. PubMed ID: 12604404
[TBL] [Abstract][Full Text] [Related]
5. Aberrant expression of TRAIL in B chronic lymphocytic leukemia (B-CLL) cells.
Secchiero P; Tiribelli M; Barbarotto E; Celeghini C; Michelutti A; Masolini P; Fanin R; Zauli G
J Cell Physiol; 2005 Nov; 205(2):246-52. PubMed ID: 15887227
[TBL] [Abstract][Full Text] [Related]
6. GM-CSF does not increase CD20 antigen expression on chronic lymphocytic leukemia lymphocytes.
Yağci M; Akar I; Sucak GT; Haznedar R
Leuk Res; 2005 Jul; 29(7):735-8. PubMed ID: 15927668
[TBL] [Abstract][Full Text] [Related]
7. Purine-rich box-1-mediated reduced expression of CD20 alters rituximab-induced lysis of chronic lymphocytic leukemia B cells.
Mankaï A; Bordron A; Renaudineau Y; Martins-Carvalho C; Takahashi S; Ghedira I; Berthou C; Youinou P
Cancer Res; 2008 Sep; 68(18):7512-9. PubMed ID: 18794139
[TBL] [Abstract][Full Text] [Related]
8. Improvement of rituximab efficiency in chronic lymphocytic leukemia by CpG-mediated upregulation of CD20 expression independently of PU.1.
Mankaï A; Buhé V; Hammadi M; Youinou P; Ghedira I; Berthou C; Bordron A
Ann N Y Acad Sci; 2009 Sep; 1173():721-8. PubMed ID: 19758221
[TBL] [Abstract][Full Text] [Related]
9. Antigen modulation followed by quantitative flow cytometry of B-chronic lymphocytic leukemia cells after treatment.
Kusenda J; Babusíková O
Neoplasma; 2004; 51(2):97-102. PubMed ID: 15190418
[TBL] [Abstract][Full Text] [Related]
10. Effects of tumour necrosis factor and alpha interferon on chronic B cell malignancies.
Bianchi AC; Heslop HE; Drexler HG; Cordingley FT; Turner M; De Mel WC; Hoffbrand AV; Brenner MK
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):317-9. PubMed ID: 3265501
[TBL] [Abstract][Full Text] [Related]
11. Three new assays for rituximab based on its immunological activity or antigenic properties: analyses of sera and plasmas of RTX-treated patients with chronic lymphocytic leukemia and other B cell lymphomas.
Beum PV; Kennedy AD; Taylor RP
J Immunol Methods; 2004 Jun; 289(1-2):97-109. PubMed ID: 15251416
[TBL] [Abstract][Full Text] [Related]
12. Veltuzumab, an anti-CD20 mAb for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and immune thrombocytopenic purpura.
Milani C; Castillo J
Curr Opin Mol Ther; 2009 Apr; 11(2):200-7. PubMed ID: 19330725
[TBL] [Abstract][Full Text] [Related]
13. Role of BAFF and APRIL in human B-cell chronic lymphocytic leukaemia.
Haiat S; Billard C; Quiney C; Ajchenbaum-Cymbalista F; Kolb JP
Immunology; 2006 Jul; 118(3):281-92. PubMed ID: 16827889
[TBL] [Abstract][Full Text] [Related]
14. Tumor cell expression of CD59 is associated with resistance to CD20 serotherapy in patients with B-cell malignancies.
Treon SP; Mitsiades C; Mitsiades N; Young G; Doss D; Schlossman R; Anderson KC
J Immunother; 2001; 24(3):263-71. PubMed ID: 11394505
[TBL] [Abstract][Full Text] [Related]
15. Cellular and molecular signal transduction pathways modulated by rituximab (rituxan, anti-CD20 mAb) in non-Hodgkin's lymphoma: implications in chemosensitization and therapeutic intervention.
Jazirehi AR; Bonavida B
Oncogene; 2005 Mar; 24(13):2121-43. PubMed ID: 15789036
[TBL] [Abstract][Full Text] [Related]
16. Comparison of fluorescein and phycoerythrin conjugates for quantifying CD20 expression on normal and leukemic B-cells.
Wang L; Abbasi F; Gaigalas AK; Vogt RF; Marti GE
Cytometry B Clin Cytom; 2006 Nov; 70(6):410-5. PubMed ID: 16967494
[TBL] [Abstract][Full Text] [Related]
17. [Density expression of the CD20 antigen on population of tumor cells in patients with chronic B-lymphocyte lymphoproliferative diseases].
Suková V; Klabusay M; Coupek P; Brychtová Y; Doubek M; Mayer J
Cas Lek Cesk; 2006; 145(9):712-6; discussion 716-7. PubMed ID: 17091727
[TBL] [Abstract][Full Text] [Related]
18. Autocrine or paracrine models of cytokine production and utilization in B-cell chronic lymphocytic leukaemia.
Foa R; Giovarelli M; Fierro MT; Bonferroni M; Forni G
Nouv Rev Fr Hematol (1978); 1988; 30(5-6):339-41. PubMed ID: 3065732
[TBL] [Abstract][Full Text] [Related]
19. Different levels of CD52 antigen expression evaluated by quantitative fluorescence cytometry are detected on B-lymphocytes, CD 34+ cells and tumor cells of patients with chronic B-cell lymphoproliferative diseases.
Klabusay M; Sukova V; Coupek P; Brychtova Y; Mayer J
Cytometry B Clin Cytom; 2007 Sep; 72(5):363-70. PubMed ID: 17428002
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of anti-CD20 treatment in patients with rheumatoid arthritis resistant to a combination of methotrexate/anti-TNF therapy.
Bokarewa M; Lindholm C; Zendjanchi K; Nadali M; Tarkowski A
Scand J Immunol; 2007 Oct; 66(4):476-83. PubMed ID: 17850593
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
